SCHEMBL2284634

SCHEMBL2284634

Cc1cc(O)c(C(=O)C=Cc2cccc(OCC(=O)N(C)C)c2)c(=O)n1C

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 3/20 0.44
KEAP1 Q14145 3/20 0.43
NFE2L2 Q16236 3/20 0.43
MAOB P27338 4/20 0.43
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
BCHE P06276 3/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
APP P05067 1/20 0.41
LMNA P02545 2/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
NPC1 O15118 1/20 0.40
PKM P14618 1/20 0.40
RAB9A P51151 1/20 0.40
MAOA P21397 1/20 0.40
SLC5A1 P13866 1/20 0.40
SLC5A2 P31639 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284630 1.00 ABCG2 (0.44) ABCG2KEAP1NFE2L2MAOBALDH1A1
SCHEMBL2277100 0.89 ABCG2 (0.47) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2283908 0.89 ABCG2 (0.47) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2283911 0.89 ABCG2 (0.47) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2277095 0.89 ABCG2 (0.47) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2284307 0.89 ABCG2 (0.48) ABCG2KEAP1NFE2L2MAOBALDH1A1
SCHEMBL2284303 0.89 ABCG2 (0.48) ABCG2KEAP1NFE2L2MAOBALDH1A1
SCHEMBL2279715 0.88 ABCG2 (0.46) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2279708 0.88 ABCG2 (0.46) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2
SCHEMBL2276772 0.87 ABCG2 (0.47) ABCG2MAOBALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 ABCG2 4878/4885KEAP1 1318/4885NFE2L2 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.